Efficacy of clomifene citrate combined Bushen Culuan Decoction for the treatment of infertility caused by polycystic ovary syndrome

A protocol of systematic review

Jing Feng, MM\textsuperscript{a}, Xiao-feng Zhang, MM\textsuperscript{b}, Jie-ning Ren, MM\textsuperscript{c}, Yu-hua Huang, MB\textsuperscript{a}, Xin Zheng, MB\textsuperscript{b,*}

Abstract

**Background:** The aim of this study is to assess the efficacy and safety of clomifene citrate combined *Bushen Culuan Decoction* (CCBCD) in treating infertility caused by polycystic ovary syndrome (PCOS).

**Methods:** We will carry out this study to identify eligible randomized controlled trials (RCTs) in Cochrane Library, PUBMED, EMBASE, Web of Science, CINAHL, and China National Knowledge Infrastructure from inception to the present. There are no limitations to the language and publication time. We will perform study selection, data extraction, and study quality assessment. If possible, a meta-analysis will be developed to judge the comparative efficacy and safety of CCBCD with other treatments.

**Results:** The results of this study will summarize current high quality RCTs to provide direct evidence of CCBCD in treating infertility in patients with PCOS.

**Conclusion:** This study may provide evidence to determine whether CCBCD is effective and safe for the treatment of infertility caused by PCOS.

**Study registration:** INPLASY202050090.

**Abbreviations:** CC = clomifene citrate, CCBCD = clomifene citrate combined *Bushen Culuan Decoction*, Cls = confidence intervals, MD = mean difference, PCOS = polycystic ovary syndrome, PRISMA = Preferred Reporting Items for Systematic review and Meta-Analysis, RCTs = randomized controlled trials.

**Keywords:** *Bushen Culuan Decoction*, clomifene citrate, efficacy, polycystic ovary syndrome, safety

1. Introduction

Polycystic ovarian syndrome (PCOS) is one of the most frequent endocrine diseases in females of reproductive age,\textsuperscript{[1-4]} with reported prevalence of 8% to 13% in such population.\textsuperscript{[5]} However, about 70% affected females are still undiagnosed.\textsuperscript{[6]} Its common clinical symptoms manifest as menstrual irregularities, infertility, hirsutism, acne, obesity, and psychological conditions.\textsuperscript{[7-10]}

Previous studies found that it is a major cause of anovulatory infertility, and also induces a high risk of complications.\textsuperscript{[11-15]} Although clomifene citrate (CC) is one of the first-line medications that can help induce ovulation in females with PCOS,\textsuperscript{[14,15]} there are still 15% to 40% of such patients who cannot ovulate after CC administration.\textsuperscript{[16]} Thus, it is necessary to explore alternative therapy adjunctive to CC. Fortunately, studies suggested that clomifene citrate combined *Bushen Culuan Decoction* (CCBCD) benefit infertility in patients with PCOS.\textsuperscript{[17-22]} However, no systematic review has addressed this topic. Thus, the aim of this study is to appraise the efficacy and safety of CCBCD for the treatment of infertility caused by PCOS.

2. Methods and analysis

2.1. Study registration

This study was registered on INPLASY202050090. We have reported this study following the guidelines of Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) Protocols.\textsuperscript{[23]}

2.2. Eligibility criteria of study selection

2.2.1. Type of studies. This study includes randomized controlled trials (RCTs) of CCBCD in treating infertility following PCOS. We will exclude all non-RCTs, such as review, non-clinical trials, and uncontrolled trials.
2.2.2. Type of participants. All eligible female adults (aged more than 18 years old) who were diagnosed as infertility caused by PCOS will be included, regardless race, country, and duration of PCOS.

2.2.3. Type of interventions. All eligible patients in the interventional group received CCBCD. All eligible participants in the control group received any treatment. However, we will exclude patients who also underwent any forms of CC, *Bushen Culuan Decoction*, or CCBCD.

2.2.4. Type of outcomes. The primary outcomes are total ovulation rate and total pregnancy rate. The secondary outcomes are levels of sex hormone (such as luteinizing hormone, follicle stimulating hormone, and androstadiendione), pregnancy loss, ectopic pregnancy, pregnancy and neonatal complications, and adverse events.

2.3. Search strategy

We will search electronic databases in Cochrane Library, PUBMED, EMBASE, Web of Science, CINAHL, and China National Knowledge Infrastructure from inception to the present. These databases will be searched for eligible RCTs published without restrictions to language and publication time. The detailed search strategy of Cochrane Library is provided in Table 1. Similar search strategies will be modified for other electronic databases.

In addition, we will retrieve other sources, such as conference abstracts, ongoing or unpublished studies from clinical trial registry, and reference lists of associated reviews.

2.4. Study selection

Two researchers will independently perform study selection by scanning titles and abstracts of all searched citations, and all unconnected studies will be removed. Then, full-text of all potential trials will be read against all inclusion criteria. If there are divergences between two researchers, we will invite a third researcher to discuss and solve the divisions. We will present study selection in a PRISMA flow chart.

2.5. Data extraction

Two researchers will independently extract data from eligible trials using pre-piloted, standardized and structured form, and any conflict will be cleared up by a third researcher through discussion. We will extract data of title, first author, country, type of PCOS, number of arms, number of patients, trial setting, trial design, trial methods, details of CCBCD and comparators, outcomes and their measurement time points, results, findings, withdrawals, and adverse events. Any disagreement will be resolved by a third researcher.

We will contact primary trial authors to request any insufficient, unclear or missing data. If we cannot obtain such data, we will perform outcome data analysis using intention-to-treat analysis.

2.6. Risk of bias assessment

The study methodological quality of all included RCTs will be assessed using Cochrane risk of bias tool. It has seven domains, and each one is further rated as “high,” “unclear,” or “low” risk of bias. If there are divergences between two researchers, we will invite a third researcher to solve those dissimilarities through discussion.

2.7. Statistical analysis

RevMan 5.3 software will be utilized for data analysis. The effect size of continuous data will be estimated using standardized mean difference (MD) and 95% confidence intervals (CIs), and that of dichotomous data will be expressed using risk ratio and 95% CIs. We will apply $I^2$ statistic to employ statistical heterogeneity. $I^2 \leq 50\%$ suggests little heterogeneity; and we will pool outcome data using a fixed-effects model; and will carry out a meta-analysis if sufficient data are extracted from included trials. $I^2 > 50\%$ exerts remarkable heterogeneity; and we will undertake subgroup analysis and meta-regression to explore possible sources of obvious heterogeneity.

2.8. Subgroup analysis

A subgroup analysis will be performed according to the different study information, patient characteristics, study quality, sample size, and outcome indicators.

2.9. Sensitivity analysis

A sensitivity analysis will be conducted to test the robustness of study findings by eliminating low quality studies.

| Table 1 | Search strategy of Cochrane Library. |
|---------|-------------------------------------|
| Number  | Search terms                                         |
| 1       | MeSH descriptor: (polycystic ovary syndrome) explode all trees |
| 2       | MeSH descriptor: (infertility) explode all trees      |
| 3       | (hormonal disorder) or (PCOS) or (menstrual irregularity) or (excess hair growth) or (hirsutism) or (acne) or (obesity) or (infertility) or (pregnancy):ti, ab, kw |
| 4       | Or 1–3                                             |
| 5       | MeSH descriptor: (clomifene) explode all trees       |
| 6       | (Bushen Culuan Decoction) explode all trees          |
| 7       | (clomifene) or (citrate) or (Serpheene) or (Chinese medicine) or (herbal medicine) or (decoction):ti, ab, kw |
| 8       | Or 5–7                                             |
| 9       | MeSH descriptor: (randomized controlled trials) explode all trees |
| 10      | MeSH descriptor: (clinical trials as topic) explode all trees |
| 11      | (random) or (randomly) or (blind) or (allocation) or (control) or (comparator) or (clinical study) or (controlled study):ti, ab, kw |
| 12      | Or 9–11                                            |
| 13      | 4 and 8 and 12                                      |
2.10. Reporting bias

Reporting bias will be identified using Funnel plot and Egger's regression test if over 10 eligible RCTs are included.[14,25]

2.11. Quality of evidence

Two researchers will appraise the quality of evidence for each outcome utilizing Grading of Recommendations Assessment Development and Evaluation.[26] Any differences will be fulfilled with the help of a third researcher through discussion or consultation.

2.12. Ethics and dissemination

This study does not need ethical approval, because it will not collect individual patient data. We will submit this study on a peer-reviewed journal or conference meeting.

3. Discussion

PCOS is the leading cause of infertility in women of reproductive age.[1–4] An increasing number of eligible trials reported the CCBCD in treating infertility in patients with PCOS.[17–22] However, no systematic review is performed to appraise the efficacy and safety of CCBCD in treating infertility in patients with PCOS. Thus, the purpose of this study is to summarize the up-to-date clinical evidence of CCBCD in the treatment of infertility caused by PCOS.

To avoid potential bias, this study will examine relevant sources as comprehensive as possible. As to the exploration of potential heterogeneity, subgroup analysis and sensitivity analysis will be conducted. This study will also identify reporting bias to avoid the bias that may affect study findings. The results of this study may provide evidence to help determine whether or not CCBCD is effective and safe in the treatment of infertility caused by PCOS.

Author contributions

Conceptualization: Jing Feng, Xiao-feng Zhang, Yu-hua Huang, Xin Zheng.
Data curation: Jing Feng, Jie-ning Ren, Xin Zheng.
Formal analysis: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Xin Zheng.
Investigation: Xin Zheng.
Methodology: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Xin Zheng.
Project administration: Xin Zheng.
Resources: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Yu-hua Huang.
Software: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Yu-hua Huang.
Supervision: Xin Zheng.
Validation: Jing Feng, Xiao-feng Zhang, Yu-hua Huang, Xin Zheng.
Visualization: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Yu-hua Huang, Xin Zheng.
Writing – original draft: Jing Feng, Jie-ning Ren, Yu-hua Huang, Xin Zheng.
Writing – review & editing: Jing Feng, Xiao-feng Zhang, Jie-ning Ren, Xin Zheng.

References

[1] Klein J, Craven M, Vugun PM. Polycystic ovarian syndrome. Adolesc Med State Art Rev 2015;26:326–42.
[2] Li S, Zhu D, Duan H, et al. The epigenomics of polycystic ovarian syndrome: from pathogenesis to clinical manifestations. Gynecol Endocrinol 2016;32:942–6.
[3] Shah R. Emerging topics in cardiometabolic and psychologic sequelae, pathogenesis, and treatment of polycystic ovarian syndrome: a review. Children (Basel) 2019;6:89.
[4] Zore T, Joshi NV, Lameya D, et al. Polycystic ovarian syndrome: long-term health consequences. Semin Reprod Med 2017;35:271–81.
[5] Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841–53.
[6] March WA, Moore VM, Wilson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51.
[7] Bachelot A. Polycystic ovarian syndrome: clinical and biological diagnosis. Ann Biol Clin (Paris) 2016;74:661–7.
[8] Anagnostou P, Tatarazos BC, Kaufman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism 2018;86:33–43.
[9] Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 2020;502:214–21.
[10] Raperport C, Homberg R. The source of polycystic ovarian syndrome. Clin Med Insights Reprod Health 2019;13:117958119871467.
[11] Seow KM, Juan CC, Hwang JL, et al. Laparoscopic surgery in polycystic ovarian syndrome: reproductive and metabolic effects. Semin Reprod Med 2008;26:101–10.
[12] Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovarian syndrome. Hum Reprod Update 2006;12:673–83.
[13] Boomsma CM, Fauzer BC, Macklon NS. Pregnancy complications in women with polycystic ovarian syndrome. Semin Reprod Med 2008;26:72–84.
[14] Begum MR, Ferdous J, Begum A, et al. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril 2009;92:853–7.
[15] Dehbashy S, Vafei H, Paransazhade MD, et al. Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome. Int J Gynaecol Obstet 2006;93:44–8.
[16] Saha L, Kaur S, Saha PK. N-acetyl cysteine in clomiphene citrate resistant polycystic ovarian syndrome: A review of reported outcomes. J Pharmacol Pharmacother 2013;4:187–91.
[17] Guo YH, Tan Y, Zou YJ, et al. Clinical observation of Bushen Chong Ou Decoction combined with clomiphene citrate tablets in treating infertility and pregnancy outcomes caused by polycystic ovary syndrome. J Hubei Univ Tradit Chin Med 2013;15:53–4.
[18] Guo YH, Qiu QM, Tan Y, et al. Clinical study on the treatment of infertility caused by polycystic ovary syndrome with Bushen Chongxin decoction combined with clomiphene citrate. Janggu Chin Med 2013;45:24–5.
[19] Liu XY. A clinical study of Bushen Chong Ou Tang combined with clomiphene citrate in the treatment of infertility caused by polycystic ovary syndrome. Biped Health 2018;27:166–7.
[20] Yang XW. Clinical observation of the combined treatment of clomiphene citrate and Bushen Chou Ou Tang in the treatment of infertility caused by polycystic ovary syndrome. Jiangxi Med 2014;49:1491–3.
[21] Chen WH. Application effect of Bushen Chong Ou Tang in the treatment of patients with polycystic ovary syndrome ovulatory dysfunction infertility. Med Theory Pract 2013;32:779–80.
[22] Fan XJ, Chen L. The effect of Bushen Chong Ou Tang on ovary function and pregnancy outcome in patients with polycystic ovary syndrome and ovulation dysfunction. Sichuan J Tradit Chin Med 2019;37:159–61.
[23] Mosher D, Shamsi A, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[24] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[25] Egger M,Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[26] Guyatt GH, Oxman A, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.